The University of Alabama (Tuscaloosa, AL, USA), Birmingham in collaboration with Altimmune Inc. (Gaithersburg, MD, USA) and Summit Biosciences (Lexington, KY, USA) developed an intranasal COVID-19 vaccine, AdCOVID, which has been designed to express RBD of the SARS-CoV-2 S protein. This evidence concerns the gene PROS1 and COVID-19.